PLASMA PROTEIN THERAPEUTICS ASSOCIATION for PLASMA PROTEIN THERAPEUTICS ASSOCIATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 23, 2012 | $56,150 | Replaced |
| 1st Quarter - Amendment | Apr 24, 2012 | $116,150 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Annual pharmaceutical fee, 340B drug pricing program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, drug shortages (PDUFA reauthorization), essential health benefits, comparative effectiveness research
Foreign entity interest: Grifols S.A., Cangene Corp.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE BIRKOFER | — |
| JOHN EVERETT CROSLAND | — |
| KYM HOWARTH KILBOURNE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.